PRKAA2 and metabolic dysfunction-associated steatotic liver disease: Therefore, investigating the downstream mechanisms of AMPK regulation in hepatic lipid metabolism can provide theoretical basis for MASLD treatment through targeted AMPK activation, but may not explain the pathogenesis of MASLD.